All Outputs (2)

Identification of the Antigens Recognised by Colorectal Cancer Patients Using Sera from Patients Who Exhibit a Crohn’s-like Lymphoid Reaction (2022)
Journal Article
Boncheva, V. B., Linnebacher, M., Kdimati, S., Draper, H., Orchard, L., Mills, K. I., O’Sullivan, G., Tangney, M., & Guinn, B. A. (2022). Identification of the Antigens Recognised by Colorectal Cancer Patients Using Sera from Patients Who Exhibit a Crohn’s-like Lymphoid Reaction. Biomolecules, 12(8), 1058. https://doi.org/10.3390/biom12081058

A Crohn’s-like lymphoid reaction (CLR) is observed in about 15% of colorectal cancer (CRC) patients and is associated with favourable outcomes. To identify the immune targets recognised by CRC CLR patient sera, we immunoscreened a testes cDNA library... Read More about Identification of the Antigens Recognised by Colorectal Cancer Patients Using Sera from Patients Who Exhibit a Crohn’s-like Lymphoid Reaction.

Oral tolerance to cancer can be abrogated by T regulatory cell inhibition (2014)
Journal Article
Whelan, M. C., Casey, G., Larkin, J. O., Guinn, B. A., O'Sullivan, G. C., & Tangney, M. (2014). Oral tolerance to cancer can be abrogated by T regulatory cell inhibition. PLoS ONE, 9(5), Article e97602. https://doi.org/10.1371/journal.pone.0097602

Oral administration of tumour cells induces an immune hypo-responsiveness known as oral tolerance. We have previously shown that oral tolerance to a cancer is tumour antigen specific, non-cross-reactive and confers a tumour growth advantage. We inves... Read More about Oral tolerance to cancer can be abrogated by T regulatory cell inhibition.